相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy
Weidong Han et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Design, synthesis and biological evaluation of acridone analogues as novel STING receptor agonists
Shi Hou et al.
BIOORGANIC CHEMISTRY (2020)
Combining microenvironment normalization strategies to improve cancer immunotherapy
Fotios Mpekris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Raluca Ioana Teleanu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation
Yewei Liu et al.
DIAGNOSTICS (2020)
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes
Christopher R. Cogle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Alyssa Vito et al.
CELLS (2020)
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents
Michael R. Horsman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
New Organometallic Ruthenium(II) Compounds Synergistically Show Cytotoxic, Antimetastatic and Antiangiogenic Activities for the Treatment of Metastatic Cancer
Yuchen Wang et al.
CHEMISTRY-A EUROPEAN JOURNAL (2020)
Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors
Hark Kyun Kim et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Molecular principles of metastasis: a hallmark of cancer revisited
Jawad Fares et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
Eavan C. McLoughlin et al.
PHARMACEUTICALS (2020)
Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists
Jihyun Hwang et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2019)
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 81 (2019)
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Asghar Fallah et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment
Maryam Ebrahimi Nik et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling
Fernanda G. Kugeratski et al.
SCIENCE SIGNALING (2019)
Hypoxia and matrix viscoelasticity sequentially regulate endothelial progenitor cluster-based vasculogenesis
Michael R. Blatchley et al.
SCIENCE ADVANCES (2019)
Collagen density regulates the activity of tumor-infiltrating T cells
Dorota E. Kuczek et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Azodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review
Rashmi Kumari et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2019)
Tumor Microenvironment as A Game Changer in Cancer Radiotherapy
Magdalena Jarosz-Biej et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Jason H. Gill et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Limitations of Anti-Angiogenic Treatment of Tumors
Domenico Ribatti et al.
TRANSLATIONAL ONCOLOGY (2019)
Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug
Jian Jiang et al.
ADVANCED MATERIALS (2019)
Vascular regulation of antitumor immunity
Lance L. Munn et al.
SCIENCE (2019)
Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment
Na Shen et al.
NANO LETTERS (2019)
Microtubule disruption changes endothelial cell mechanics and adhesion
Andreas Weber et al.
SCIENTIFIC REPORTS (2019)
Tumor Endothelial Heterogeneity in Cancer Progression
Nako Maishi et al.
CANCERS (2019)
Hypoxia-Modified Cancer Cell Metabolism
Wafaa Al Tameemi et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Fusion protein tTF-EG3287 induces occlusion of tumor vessels and impairs tumor growth in human colon cancer
G. Q. Qiu et al.
NEOPLASMA (2019)
Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously
Jian Jiang et al.
BIOMATERIALS SCIENCE (2019)
Combination of nanotechnology with vascular targeting agents for effective cancer therapy
Rana Jahanban-Esfahlan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA
Amy Y. Shih et al.
BIOPHYSICAL JOURNAL (2018)
A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype
Xueping Lei et al.
CANCER LETTERS (2018)
An overview on Vadimezan (DMXAA): The vascular disrupting agent
Amir Daei Farshchi Adli et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Thomas M. Ashton et al.
CLINICAL CANCER RESEARCH (2018)
The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats
Yewei Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Contribution of Tumor Endothelial Cells in Cancer Progression
Kyoko Hida et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer
Tuo Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2018)
M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
Magdalena Jarosz-Biej et al.
PLOS ONE (2018)
The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
Rindert Missiaen et al.
SEMINARS IN CANCER BIOLOGY (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Ryszard Smolarczyk et al.
SCIENTIFIC REPORTS (2018)
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Ahmed M. E. Abdalla et al.
THERANOSTICS (2018)
Identification of -Mangostin as an Agonist of Human STING
Yibo Zhang et al.
CHEMMEDCHEM (2018)
Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy
Anette Weyergang et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Biophysics of Tumor Microenvironment and Cancer Metastasis - A Mini Review
Bashar Emon et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2018)
Matrix stiffening promotes a tumor vasculature phenotype
Francois Bordeleau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them
Jie Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
The development and use of vascular targeted therapy in ovarian cancer
Dana M. Chase et al.
GYNECOLOGIC ONCOLOGY (2017)
Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents
Minfeng Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
A phase II study of combretastatin A4-phosphate (CA4P) in the treatment of welldifferentiated, low-to intermediate-grade, unresectable, recurrent, or metastatic pancreatic, or GI neuroendocrine tumors/carcinoid (GI-NETs/PNETs) with elevated biomarkers.
Steven K. Libutti et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts
Jon-Vidar Gaustad et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Veronica Huber et al.
SEMINARS IN CANCER BIOLOGY (2017)
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Khaled Seidi et al.
TUMOR BIOLOGY (2017)
Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P
Yewei Liu et al.
ONCOTARGET (2017)
RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice
Rana Jahanban-Esfahlan et al.
SCIENTIFIC REPORTS (2017)
The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
Julia M. Weiss et al.
ONCOIMMUNOLOGY (2017)
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins
Tobias G. Kapp et al.
SCIENTIFIC REPORTS (2017)
Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent
Michael R. Horsman
ACTA ONCOLOGICA (2017)
Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer
D. W. Siemann et al.
CANCER INVESTIGATION (2017)
Current progress in antivascular tumor therapy
Yi-Ju Ho et al.
DRUG DISCOVERY TODAY (2017)
Suppression of angiogenesis and tumour progression by combretastatin and derivatives
G. V. Sherbet
CANCER LETTERS (2017)
Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors
Annalisa Trenti et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Hong Jiang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
A poly(L-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor
Tianzhou Liu et al.
ACTA BIOMATERIALIA (2017)
Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extended and Sequentially Controllable Drug Release
Hangxiang Wang et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
Linh Nguyen et al.
BMC CANCER (2016)
Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway
Jie Mao et al.
CANCER LETTERS (2016)
The expanding regulatory network of STING-mediated signaling
Guy Surpris et al.
CURRENT OPINION IN MICROBIOLOGY (2016)
Stimulator of interferon genes (STING): A new chapter in virus-associated cancer research. Lessons from wild-derived mouse models of innate immunity
Alexander Poltorak et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Ewa Maj et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors
Constanze Hantel et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis
Souvik Banerjee et al.
MOLECULES (2016)
Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status
Karol Jaroch et al.
PHARMACOLOGICAL REPORTS (2016)
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Caroline Wigerup et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Hypoxic control of metastasis
Erinn B. Rankin et al.
SCIENCE (2016)
Vascular disrupting activity of combretastatin analogues
Elena Porcu et al.
VASCULAR PHARMACOLOGY (2016)
A randomized Phase II trial of the tumor vascular disrupting agent CACA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
Edward B. Garon et al.
ONCOTARGETS AND THERAPY (2016)
Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions
Wenjie Liang et al.
ONCOTARGET (2016)
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMPSTING-IRF3 Mediated Innate Immune Response
Tiejun Li et al.
SCIENTIFIC REPORTS (2016)
The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
Min Su et al.
SCIENTIFIC REPORTS (2016)
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Emily Curran et al.
CELL REPORTS (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
Rat and human STINGs profile similarly towards anticancer/antiviral compounds
Heng Zhang et al.
SCIENTIFIC REPORTS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Combretastatins: More Than Just Vascular Targeting Agents?
Lisa M. Greene et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
Judy R. van Beijnum et al.
PHARMACOLOGICAL REVIEWS (2015)
Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF121 Combined with IL-12 Gene Therapy
Agnieszka Ciomber et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2014)
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model
Chang Hoon Moon et al.
INVESTIGATIONAL NEW DRUGS (2014)
DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization
Charlene M. Downey et al.
PLOS ONE (2014)
Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
Pu Gao et al.
CELL REPORTS (2014)
Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
Rebecca Suk Heist et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anticancer Flavonoids Are Mouse-Selective STING Agonists
Sujeong Kim et al.
ACS CHEMICAL BIOLOGY (2013)
Using macrophage activation to augment immunotherapy of established tumours
Z. G. Fridlender et al.
BRITISH JOURNAL OF CANCER (2013)
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
S. M. Tijono et al.
BRITISH JOURNAL OF CANCER (2013)
Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08)
Martin Frueh et al.
CLINICAL LUNG CANCER (2013)
Combination of vascular disrupting agents and ionizing radiation
Celine Clemenson et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid
Joseph Conlon et al.
JOURNAL OF IMMUNOLOGY (2013)
Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy
Xue-Yuan Wu et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2013)
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Jiaxi Wu et al.
SCIENCE (2013)
Heterogeneity of Tumor Endothelial Cells Comparison between Tumor Endothelial Cells Isolated from High- and Low-Metastatic Tumors
Noritaka Ohga et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments
Linh Nguyen et al.
BMC CANCER (2012)
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Dan M. Patterson et al.
CLINICAL CANCER RESEARCH (2012)
Mechanical compression drives cancer cells toward invasive phenotype
Janet M. Tse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
Luana Schito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
Triantafyllos Stylianopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
Sarah Jane Lunt et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation
Lotte B. Bertelsen et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2011)
The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors
Haruko Daga et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents
Ishwaria M. Subbiah et al.
ONCOLOGIST (2011)
Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
Joong Bae Ahn et al.
CANCER LETTERS (2010)
Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors
Jaekwang Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
Colin J. Mooney et al.
THYROID (2009)
Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)
Liang-Chuan S. Wang et al.
NEOPLASIA (2009)
Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials
Michael B. Jameson et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Tumor cell metabolism: Cancer's Achilles' heel
Guido Kroemer et al.
CANCER CELL (2008)
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors
Gillian M. Tozer et al.
CANCER RESEARCH (2008)
The Angiopoietin-2 Gene of Endothelial Cells is Up-Regulated in Hypoxia by a HIF Binding Site Located in Its First Intron and by the Central Factors GATA-2 and Ets-1
Marie-Pierre Simon et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Huafeng Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Temporal heterogeneity in blood supply in human tumor xenografts
Kjetil G. Brurberg et al.
NEOPLASIA (2008)
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Mark W. Dewhirst et al.
NATURE REVIEWS CANCER (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting
Qi Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis
Zachary J. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
Howard W. Salmon et al.
CLINICAL CANCER RESEARCH (2006)
Antitumor effect of RGD-4C-GG-D(KLAKLAK)(2) peptide in mouse B16(F10) melanoma model
Ryszard Smolarczyk et al.
ACTA BIOCHIMICA POLONICA (2006)
Chemokines direct endothelial progenitors into tumor neovessels
H Spring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
DW Siemann et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Cellular abnormalities of blood vessels as targets in cancer
P Baluk et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Relationship between tumour enclothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
LM Ching et al.
BRITISH JOURNAL OF CANCER (2004)
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate
IG Kirwan et al.
CLINICAL CANCER RESEARCH (2004)
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
DJ Ceradini et al.
NATURE MEDICINE (2004)
Vascular endothelial growth factor and angiogenesis
A Hoeben et al.
PHARMACOLOGICAL REVIEWS (2004)
Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation
O Stoeltzing et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors
P Baluk et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
K Hori et al.
BRITISH JOURNAL OF CANCER (2003)
The vascular network of tumours - what is it not for?
E Sivridis et al.
JOURNAL OF PATHOLOGY (2003)
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy
S Ran et al.
NEOPLASIA (2003)
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
MB Jameson et al.
BRITISH JOURNAL OF CANCER (2003)
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-I knockout mice
L Zhao et al.
BRITISH JOURNAL OF CANCER (2002)
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
LM Ching et al.
BRITISH JOURNAL OF CANCER (2002)
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors
S Morikawa et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
W Landuyt et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
